首页> 外文期刊>Journal of neuro-oncology. >Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery
【24h】

Factors affecting early versus late remission in acromegaly following stereotactic radiosurgery

机译:在立体定向放射外科术后患者早期影响早期缓解的因素

获取原文
获取原文并翻译 | 示例
           

摘要

Stereotactic radiosurgery (SRS) is a well-established treatment modality for patients with acromegaly. Our previously published study demonstrated a median time to remission of 29 months. This study aims to identify factors affecting the timing of remission and also to quantify the rate of late remission. This is a retrospective analysis of acromegaly patients who underwent SRS between 1988 and 2016. Early and late remissions were defined based on our prior median remission time of 29 months. The median imaging and endocrine follow-ups are 66 and 104.8 months, respectively. Multivariate analysis was conducted to analyze factors leading to late remission. A total number of 157 patients, of those 102 (64.9%) patients achieved remission. of those 102 patients, 62 patients (60.7%) had remission in less than 29 months (early remission) whereas 40 patients (39.3%) achieved remission later than (late remission) 29 months. The two groups differed significantly in the time interval between the last resection and the first SRS (p = 0.040) whole sella radiosurgery (p = 0.025) or radiosurgery to the cavernous sinus (p = 0.041). Competing risk analysis showed the interval between resection and SRS was significantly longer in the late remission group (HR 1.013, 95% CI 1.004-1.02; p = 0.007). Fifty-one of 157 patients (32.5%) developed a new endocrine deficiency following SRS. Those with shorter time between resection and SRS were more likely to achieve early remission. While most patients achieve remission in less than 4 years, the latency of effect with SRS yields a small percentage of patients achieving remission beyond that time point.
机译:定向术放射牢(SRS)是患者患者患者的成熟治疗方式。我们之前发表的研究表明,29个月的缓解了中位数。本研究旨在识别影响缓解时间的因素,也可以量化晚期缓解率。这是对1988年至2016年期间患者的痛苦患者的回顾性分析。早期和延迟解除是根据我们的前期缓解时间为29个月。中位数成像和内分泌后续随访分别为66和104.8个月。进行多元分析以分析导致缓解晚期的因素。总数为157名患者,其中102名(64.9%)患者取得了缓解。在这102名患者中,62名患者(60.7%)在不到29个月(早期缓解)中有缓解,而40名患者(39.3%)在29个月后达到缓解(39.3%)。两组在最后一次切除和第一个SRS(P = 0.040)的时间间隔中有显着不同(P = 0.040)整个SELLA放射牢(P = 0.025)或通孔前泌乳术(P = 0.041)。竞争风险分析显示切除术和SRS之间的间隔在后期缓解组(HR 1.013,95%CI 1.004-1.02; P = 0.007)中。 157名患者中的五十一(32.5%)开发了SRS后的新内分泌缺乏。切除术和SRS较短的人更有可能实现早期缓解。虽然大多数患者在不到4年的时间内实现缓解,但患有SRS效应的潜伏期产生了一小部分患者,以实现超出该时间点的缓解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号